Journal
CLINICAL CANCER RESEARCH
Volume 26, Issue 23, Pages 6086-6101Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-3870
Keywords
-
Categories
Funding
- Spanish Ministry of Economy and Competitiveness/ISCIII-FEDER [PI17/00199]
- Generalitat de Catalunya [2017-SGR-225]
- Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 2017-0494]
- Fundacion Sales
- Fundacion Bunge Born
- Richard Lounsbery Foundation
Ask authors/readers for more resources
Galectins are an endogenous family of beta-galactoside-binding proteins that play complex and multifaceted roles at various stages of cancer progression, including modulation of tumor cell proliferation, signaling, adhesion, migration, invasion, epithelial-mesenchymal transition, angiogenesis, and immune escape. Recently, galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies. Here, we present an integrated approach to the pleiotropic functions of galectins and discuss their emerging roles with respect to mechanisms of resistance or sensitivity to anticancer therapies. Taken together, these findings suggest that targeting galectins and/or their glycosylated ligands may help to overcome resistance and to increase the clinical efficacy of anticancer strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available